CXCL10 levels were significantly greater in severe SARS-CoV-2-positive patients than in mild or moderate patients, implying that CXCL10 could be a useful biomarker for distinguishing between mild/moderate and severe COVID-19 patients and predicting disease severity. Here, CXCL10 is linked to COVID-19.